JP2010525836A - ヒト造血幹細胞のｅｘｖｉｖｏ増殖 - Google Patents

ヒト造血幹細胞のｅｘｖｉｖｏ増殖 Download PDF

Info

Publication number
JP2010525836A
JP2010525836A JP2010507549A JP2010507549A JP2010525836A JP 2010525836 A JP2010525836 A JP 2010525836A JP 2010507549 A JP2010507549 A JP 2010507549A JP 2010507549 A JP2010507549 A JP 2010507549A JP 2010525836 A JP2010525836 A JP 2010525836A
Authority
JP
Japan
Prior art keywords
cells
medium
human
cell
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010507549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525836A5 (https=
Inventor
チェンチェン チャン，
ハーベイ ロディッシュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of JP2010525836A publication Critical patent/JP2010525836A/ja
Publication of JP2010525836A5 publication Critical patent/JP2010525836A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010507549A 2007-05-04 2008-05-02 ヒト造血幹細胞のｅｘｖｉｖｏ増殖 Pending JP2010525836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92766807P 2007-05-04 2007-05-04
US1400607P 2007-12-14 2007-12-14
PCT/US2008/062365 WO2008137641A2 (en) 2007-05-04 2008-05-02 Ex vivo expansion of human hematopoietic stem cells

Publications (2)

Publication Number Publication Date
JP2010525836A true JP2010525836A (ja) 2010-07-29
JP2010525836A5 JP2010525836A5 (https=) 2012-07-12

Family

ID=39790348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507549A Pending JP2010525836A (ja) 2007-05-04 2008-05-02 ヒト造血幹細胞のｅｘｖｉｖｏ増殖

Country Status (4)

Country Link
US (2) US8609411B2 (https=)
EP (1) EP2155862A2 (https=)
JP (1) JP2010525836A (https=)
WO (1) WO2008137641A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140121454A (ko) * 2012-01-27 2014-10-15 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
WO2014171486A1 (ja) * 2013-04-17 2014-10-23 日産化学工業株式会社 培地組成物及び当該培地組成物を用いた赤血球の製造方法
JP2017513897A (ja) * 2014-04-22 2017-06-01 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
JP2017517259A (ja) * 2014-05-22 2017-06-29 フレッド ハッチンソン キャンサー リサーチ センター Ｌｉｌｒｂ２およびｎｏｔｃｈを介した造血前駆細胞の拡大培養
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
JP2019201599A (ja) * 2018-05-24 2019-11-28 国立研究開発法人国立国際医療研究センター 造血幹細胞を維持培養するための培地、及びそれを用いた培養方法
US10590380B2 (en) 2012-07-24 2020-03-17 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139271B2 (ja) * 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
JP5435388B2 (ja) 2008-04-25 2014-03-05 国立大学法人 千葉大学 インスリン様増殖因子結合タンパク質を含有するＷｎｔシグナル伝達阻害剤
US20110280861A1 (en) * 2008-08-08 2011-11-17 Massachusetts Institute Of Technology Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
JP5602850B2 (ja) 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
AU2012335070A1 (en) 2011-11-11 2014-05-29 Bio-Ess Laboratories, Llc Kit comprising serum replacement and labile factors
WO2014127170A1 (en) * 2013-02-13 2014-08-21 Wake Forest University Health Sciences Bioengineered liver constructs and methods relating thereto
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN103509101B (zh) * 2013-08-12 2016-11-02 中国科学院广州生物医药与健康研究院 一种扩增脐带血造血干细胞的细胞因子及其培养基
KR20160125352A (ko) 2013-12-20 2016-10-31 이센셜 파마수티컬스 엘엘씨 세포 배양용 배지
IL255664A0 (en) * 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083845A2 (en) * 2001-04-10 2002-10-24 Viacell, Inc. Modulation of primary stem cell differentiation
WO2006127809A2 (en) * 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
AU7476694A (en) 1993-07-29 1995-02-28 Systemix, Inc. Novel stem cell marker
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
WO1995008105A1 (en) 1993-09-17 1995-03-23 Systemix, Inc. Method for obtaining a cell population enriched in stem cells and compositions derived therefrom
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1997021824A2 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AU4320499A (en) 1998-06-02 1999-12-20 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
WO2000052167A1 (en) 1999-03-02 2000-09-08 Regeneron Pharmaceuticals, Inc. Angiopoietin-related protein and nucleic acids
WO2002078449A2 (en) * 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
EP1308511A1 (en) 2001-10-31 2003-05-07 Mermaid Pharmaceuticals GmbH Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature.
DE60231328D1 (de) 2001-12-28 2009-04-09 Asubio Pharma Co Ltd Cofilin zur förderung der proliferation und/oder differenzierung hämatopoetischer stammzellen und/oder hämatopoetischer vorläuferzellen
WO2004046312A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20050032122A1 (en) 2003-08-06 2005-02-10 Shiaw-Min Hwang Optimizing culture medium for CD34<+> hematopoietic cell expansion
WO2006045064A2 (en) 2004-10-20 2006-04-27 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083845A2 (en) * 2001-04-10 2002-10-24 Viacell, Inc. Modulation of primary stem cell differentiation
WO2006127809A2 (en) * 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5010008912; ＺＨＡＮＧ　ＣＨＥＮＧ　ＣＨＥＮＧ: ＮＡＴＵＲＥ　ＭＥＤＩＣＩＮＥ Ｖ１２　Ｎ２, 20060122, Ｐ１-１４, ＮＡＴＵＲＥ　ＰＵＢＬＩＳＨＩＮＧ　ＧＲＯＵＰ *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140121454A (ko) * 2012-01-27 2014-10-15 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
JP2015504902A (ja) * 2012-01-27 2015-02-16 ユニヴェルスィテ・ドゥ・モントリオール ピリミド［４，５−ｂ］インドール誘導体及び造血幹細胞の増殖におけるその使用
KR102098122B1 (ko) 2012-01-27 2020-04-07 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
US10336747B2 (en) 2012-01-27 2019-07-02 Université de Montréal Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US11371013B2 (en) 2012-07-24 2022-06-28 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10590380B2 (en) 2012-07-24 2020-03-17 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
JPWO2014171486A1 (ja) * 2013-04-17 2017-02-23 日産化学工業株式会社 培地組成物及び当該培地組成物を用いた赤血球の製造方法
WO2014171486A1 (ja) * 2013-04-17 2014-10-23 日産化学工業株式会社 培地組成物及び当該培地組成物を用いた赤血球の製造方法
JP2017513897A (ja) * 2014-04-22 2017-06-01 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
US10647718B2 (en) 2014-04-22 2020-05-12 Universitéde Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
JP2017517259A (ja) * 2014-05-22 2017-06-29 フレッド ハッチンソン キャンサー リサーチ センター Ｌｉｌｒｂ２およびｎｏｔｃｈを介した造血前駆細胞の拡大培養
JP2019201599A (ja) * 2018-05-24 2019-11-28 国立研究開発法人国立国際医療研究センター 造血幹細胞を維持培養するための培地、及びそれを用いた培養方法
JP7217921B2 (ja) 2018-05-24 2023-02-06 国立研究開発法人国立国際医療研究センター 造血幹細胞を維持培養するための培地、及びそれを用いた培養方法

Also Published As

Publication number Publication date
EP2155862A2 (en) 2010-02-24
WO2008137641A3 (en) 2009-03-05
US8609411B2 (en) 2013-12-17
WO2008137641A2 (en) 2008-11-13
US20140308747A1 (en) 2014-10-16
US20110117061A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
US8609411B2 (en) Ex vivo expansion of human hematopoietic stem cells
US8617885B2 (en) Cultured hematopoietic stem cells and method for expansion and analysis thereof
US8506955B2 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
US6586192B1 (en) Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
CA2898180C (en) Reprogramming of human endothelium into hematopoietic multi-lineage progenitors by defined factors
CA2236263C (en) Methods for use of mpl ligands with primitive human stem cells
KR20090045886A (ko) 혈관 콜로니 형성 세포
JP2002527101A (ja) ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進
KR20200010198A (ko) 조혈 이식체의 개선 방법
AU755344B2 (en) Expanded and genetically modified populations of human hematopoietic stem cells
AU2002301459B2 (en) Expanded and genetically modified populations of human hematopoietic stem cells
Oates Thrombopoietin mediated regulation of murine hematopoietic progenitors
Zandstra Cytokine-dependent regulation of human hematopoietic cell self-renewal and differentiation in suspension cultures
Su Ex vivo expansion of hematopoietic stem and progenitor cells from umbilical cord blood: Cytokine combinations, platelet-derived growth factor and stromal cell support
Storb 1Hematopoietic Stem Cell Transplantation: Yesterday, Today and Tomorrow
SCHEDING et al. Characterization of Purified and Ex Vivo Manipulated Human Hematopoietic Progenitor and Stem Cells in Xenograft Recipients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130709